PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) announced it will participate in the 38th Annual Roth Conference, scheduled for March 22 to March 24 in Dana Point, California.
The company said Executive Chairman and Chief Executive Officer Dr. Raza Bokhari will take part in a fireside chat on Tuesday, March 24, where he will discuss Medicus’ clinical development programs and strategy.
The discussion will include updates on the company’s SkinJect program, a localized immuno-oncology treatment being developed for non-melanoma skin diseases such as basal cell carcinoma and Gorlin syndrome.
Medicus said Bokhari will also address the development of Teverelix, a gonadotropin-releasing hormone antagonist being studied for patients with cardiovascular high-risk advanced prostate cancer and acute urinary retention relapse linked to enlarged prostate.
The company said its strategy is to advance selected therapies through Phase 2 clinical studies before pursuing licensing agreements or strategic partnerships with larger pharmaceutical companies for later-stage development and commercialization.
The fireside chat will be hosted by Roth Capital Partners Managing Director and Senior Research Analyst Jonathan Aschoff.
A webcast of the session will be available to registered conference attendees, and Medicus executives will hold meetings with institutional investors and potential partners during the event.
Additional information about the conference is available at https://www.roth.com/conferences.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.